Skip to content

Kura Oncology, Inc.

KURA

CIK 0001422143

← back to feed
Revenue (TTM)
$68.41M
+25.2% YoY Q1 May 2026
Net Income (TTM)
−$271M
−60.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$3.09
−57.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-432.9%
Q1 May 2026
Net Margin
-396.1%
Q1 May 2026
Free Cash Flow (TTM)
−$243.04M
Q1 May 2026
Cash
$39.08M
Q1 May 2026
Total Debt
$9.75M
Q1 May 2026
Shares Outstanding
88.77M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings